We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 561

CCI investigates Athletics Federation of India and director general of health services
  • Vaish Associates Advocates
  • India
  • April 14 2016

By an order dated March 16 2016 the Competition Commission of India (CCI) ordered a detailed investigation into the Athletics Federation of India

GSK changes approach to patents in developing countries
  • Dehns
  • India
  • April 7 2016

GlaxoSmithKline (GSK), one of the world's leading pharmaceutical companies, recently announced that it is adopting a new approach to patenting its

COMPAT directs re-consideration of matter against Director General of Health Services & Others
  • Vaish Associates Advocates
  • India
  • April 4 2016

COMPAT by its order dated March 1, 2016 has set-aside the decision of CCI whereby CCI has refused to order investigation against the Director General

Controller refuses plea for compulsory licensing
  • RNA, Intellectual Property Attorneys
  • India
  • March 29 2016

This article summarizes the latest decision on an application filed by Lee Pharma, a Hyderabad based pharmaceutical company to grant Compulsory

Infringer gets a rap on the knuckles
  • RNA, Intellectual Property Attorneys
  • India
  • March 29 2016

This is an order passed by the Delhi High Court in an application to set aside the ex parte injunction, granted in favour of Win-Medicare Pvt. Ltd

Patents - Use of compound by way of particular dosage, not patentable
  • Lakshmikumaran & Sridharan
  • India
  • March 4 2016

The Indian Patent Office at Kolkata has rejected the patent application of 'Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo

Singapore Healthcare Newsletter February 2016
  • Baker & McKenzie
  • India, Singapore, South Korea
  • February 29 2016

Following the first chapter on "The Creative Destruction of Healthcare", Chapter 2 of The HealthTech Report on Data-driven Healthcare was launched in

Roche Vs Cipla: Final leg of battle over Tarceva Patent
  • RNA, Intellectual Property Attorneys
  • India
  • February 2 2016

In the final leg of battle over Tarceva patent, Cipla has approached Supreme Court challenging High Court's Order holding it guilty of infringing

Sidley Global Pricing newsletter - V4 2016
  • Sidley Austin LLP
  • United Kingdom, USA, France, Germany, India, Netherlands, Spain, Sweden, Australia, Belgium, Canada, China, European Union
  • January 27 2016

The Australian Pharmaceutical Benefits Pricing Authority (PBPA) ceased operations on April 1, 2014, in a move by the government to improve drug

Lee pharma’s compulsory license application for saxagliptin rejected by Indian Patent Office
  • Khaitan & Co
  • India
  • January 22 2016

In an order dated 19 January 2016 (Order), the Controller General of Patents and Trademarks (CGPTM) rejected the application for Compulsory License